O2 RegenTech

Cost-effective, easy-to-use wound care solutions


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

O2 RegenTech: Fast Facts

Diabetes is a massive problem affecting millions of individuals worldwide. Many develop ulcers on their feet that don’t heal (i.e., chronic wounds) leaving them open to a range of future complications, including limb amputation. In fact, worldwide, a leg is lost to diabetes every 30 seconds. Providing oxygen is the gold standard treatment to stop a diabetic chronic wound from progressing to limb amputation. Existing oxygen therapy solutions are cumbersome and expensive.

Our novel platform biopolymer technology, OXAID™, will be the first on the market to combine the benefits of providing oxygen with a moist and antimicrobial healing environment in a cost-effective and easy-to-use dressing to promote chronic wound healing. The OXAID™ biopolymer can be formulated into a number of different dressing types to treat different types of wounds.

No Effective Treatments Available

There are more than 30 million diabetics in the United States alone. An astonishing 1.7 million new cases are diagnosed every single year. As if that weren't enough, global data from the World Health Organization shows that 422 million people suffer from diabetes worldwide. About 25% of diabetics will be diagnosed with a diabetic foot ulcer, i.e., chronic wound, and roughly 20% of these cases will result in lower extremity amputations.

One-of-a-Kind Solution

O2 RegenTech solves the problem of chronic, nearly-impossible-to-heal wounds with OXAID™ biopolymer technology, a cost-effective and easy-to-use wound care solution that can be applied as a primary approach - without the need for additional products or devices.

OXAID™ is the only solution available that combines all three of the necessary components – oxygen, moisture, and an antimicrobial environment – into one simple dressing to help chronic wounds heal and does so at a substantially lower cost than other oxygen delivery systems and devices.

Traction & Accomplishments

Our initial product, OXAID™ Hydrogel Sheet Dressing, has been fully developed. Two more OXAID™ dressing products are in development. OXAID™ has been evaluated during the University of Akron I‑Corps, I-Corps@Ohio, and National Science Foundation Boot Camp customer discovery programs. Prototypes have been evaluated by prominent wound care physicians and podiatrists (including Kent State University College of Podiatric Medicine). Various animal studies have been completed to demonstrate safety and efficacy.

Meet the Team

Andreas Inmann, PhD, MBA

  • Entrepreneur, engineer, scientist
  • 20+ years of experience in commercializing medical devices and diagnostic/surgical tools
  • Extensive experience in startups (MetaCure, NDI Medical), spin-offs (SPR Therapeutics, Checkpoint Surgical), research (USC-AMI), business development, technology evaluation, product vision, clinical/regulatory/quality affairs, marketing, and strategy development

Nic D. Leipzig, PhD

  • Robert Iredell Associate Professor at the University of Akron
  • Significant expertise in functional tissue regeneration and applied biomaterials including wound healing applications
  • Appointments in Biomedical Engineering and the Integrated Biosciences Program at the University of Akron and in the Faculty of Medicine at Case Western Reserve University
  • Inventor of OXAID™ biopolymer technology

We have available to us two expert consultants in material science, biopolymer synthesis, and hydrogel manufacturing:

Rebecca M. Schur, PhD

  • PhD in Biomedical Engineering from Case Western Reserve University
  • BS and MS in Materials Science & Engineering from Cornell University
  • 10 years of experience in biomaterials research
  • Has developed natural and synthetic biopolymers and nanoparticles for therapeutic, diagnostic, and adhesive applications
  • Led all testing and characterization efforts of our hydrogel sheet dressing product

Abdullah Al Loman, PhD, MBA

  • PhD in Chemical & Biomolecular Engineering from the University of Akron
  • MBA from the University of Akron; BS in Chemical Engineering from Bangladesh University of Engineering & Technology
  • 8 years of experience in biotechnology research and bioprocess development
  • Has developed and optimized processes to produce biodegradable polymers and chemicals from renewable sources
  • Has been instrumental in translation of OXAID biopolymer synthesis to a pilot setup
  • Led the transfer and pilot setup of our synthesis and manufacturing process

Our advisory board is comprised of experienced, high profile individuals in the wound care space.

Dr. Thomas E. Serena, MD, FACS, FACHM, MAPWCA

  • Founder, CEO, and Medical Director of SerenaGroup®, a leading provider in wound care and hyperbaric treatment, operating wound care centers across the United States
  • President at Association for the Advancement of Wound Care
  • Former President of the American Professional Wound Care Association

Dr. Windy E. Cole, DPM

  • Director of Wound Care Research at Kent State University College of Podiatric Medicine
  • Director of Wound Care Services at Cleveland Regency Hospitals
  • Medical Director at University Hospitals Ahuja Wound Care Center
  • Fellow of the American College of Foot and Ankle Surgeons

Dr. Bryan D. Caldwell, DPM, MD

  • Dean, School of Podiatric Medicine at Barry University
  • Former Assistant Dean of Clinical Education and Operations at Kent State University College of Podiatric Medicine

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.